Nektar Therapeutics (NASDAQ:NKTR) Sets New 52-Week High - Time to Buy?

Key Points

• Nektar shares reached a new 52-week high of $83.76 (last $83.22) on strong volume, up about 2.4%, with a market cap near $2.39 billion and positive short‑term momentum (50‑day $70.31, 200‑day $57.95).
• Analysts are largely bullish — the consensus is a Moderate Buy with an average price target of $128.13 (nine Buys, one Hold, one Sell) after an earnings quarter that beat EPS and revenue estimates.
• Offsetting upside, multiple class‑action filings allege investor harm (deadline to seek lead‑plaintiff status May 5, 2026), which could bring legal costs and short‑term volatility despite bullish expectations for upcoming REZOLVE‑AA data.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) shares reached a new 52-week high on Thursday . The company traded as high as $83.76 and last traded at $83.22, with a volume of 527547 shares changing hands. The stock had previously closed at $81.26.

Key Headlines Impacting Nektar Therapeutics

Here are the key news stories impacting Nektar Therapeutics this week:

• Positive Sentiment: Bullish readthrough on upcoming AA data — an investor/author predicts the upcoming REZOLVE‑AA (AA) dataset will be positive, which supports upside expectations for revenue and program valuation. Nektar Therapeutics Upcoming AA Data Prediction: Why I Think It Will Be Positive
• Negative Sentiment: Multiple class‑action filings and numerous law‑firm notices allege investor harm tied to disclosures from Feb 26, 2025–Dec 15, 2025; several firms are soliciting lead plaintiffs and remind investors the May 5, 2026 deadline to seek lead‑plaintiff status — this raises potential legal costs, settlement risk and short‑term volatility. Representative filings/alerts: ROSEN - Encourages Nektar Investors to Secure Counsel Glancy Prongay Wolke - Opportunity to Lead Securities Fraud Lawsuit Faruqi & Faruqi - Equity Alert Levi & Korsinsky - Investor Alert Pomerantz - Class Action Filed Bronstein Gewirtz & Grossman - Urges Investors to Act The Gross Law Firm - Shareholder Alert Bernstein Liebhard - Shareholder Alert

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on NKTR. Wall Street Zen raised shares of Nektar Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, April 11th. TD Cowen assumed coverage on shares of Nektar Therapeutics in a research report on Tuesday, March 17th. They set a "buy" rating on the stock. Oppenheimer reissued an "outperform" rating and set a $140.00 target price on shares of Nektar Therapeutics in a research report on Friday, March 13th. Wedbush started coverage on Nektar Therapeutics in a report on Tuesday, March 24th. They set a "neutral" rating and a $70.00 price target on the stock. Finally, Citigroup lifted their price target on Nektar Therapeutics from $102.00 to $123.00 and gave the stock a "buy" rating in a report on Monday, March 16th. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $128.13.

Nektar Therapeutics Stock Up 2.4%

The stock has a 50-day simple moving average of $70.31 and a 200-day simple moving average of $57.95. The firm has a market capitalization of $2.39 billion, a PE ratio of -8.16 and a beta of 1.16.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last released its earnings results on Thursday, March 12th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.69) by $0.91. Nektar Therapeutics had a negative return on equity of 386.16% and a negative net margin of 297.07%.The business had revenue of $21.81 million during the quarter, compared to the consensus estimate of $10.44 million. Equities analysts forecast that Nektar Therapeutics will post -0.72 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Howard W. Robin sold 423 shares of Nektar Therapeutics stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $73.00, for a total value of $30,879.00. Following the completion of the transaction, the chief executive officer owned 75,489 shares in the company, valued at $5,510,697. This trade represents a 0.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jonathan Zalevsky sold 3,867 shares of Nektar Therapeutics stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $35.67, for a total transaction of $137,935.89. Following the completion of the transaction, the insider owned 21,354 shares of the company's stock, valued at $761,697.18. The trade was a 15.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 4,470 shares of company stock valued at $181,955 in the last quarter. Corporate insiders own 5.25% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. BNP Paribas Financial Markets increased its position in shares of Nektar Therapeutics by 93.8% in the third quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 210 shares during the last quarter. Deutsche Bank AG increased its holdings in shares of Nektar Therapeutics by 0.8% in the 4th quarter. Deutsche Bank AG now owns 90,743 shares of the biopharmaceutical company's stock worth $3,837,000 after buying an additional 743 shares during the last quarter. Bayforest Capital Ltd increased its holdings in shares of Nektar Therapeutics by 51.3% in the 4th quarter. Bayforest Capital Ltd now owns 2,541 shares of the biopharmaceutical company's stock worth $107,000 after buying an additional 862 shares during the last quarter. FNY Investment Advisers LLC increased its holdings in shares of Nektar Therapeutics by 70.6% in the 3rd quarter. FNY Investment Advisers LLC now owns 2,602 shares of the biopharmaceutical company's stock worth $148,000 after buying an additional 1,077 shares during the last quarter. Finally, XTX Topco Ltd increased its holdings in shares of Nektar Therapeutics by 22.0% in the 4th quarter. XTX Topco Ltd now owns 7,196 shares of the biopharmaceutical company's stock worth $304,000 after buying an additional 1,299 shares during the last quarter. 75.88% of the stock is currently owned by hedge funds and other institutional investors.

Nektar Therapeutics Company Profile

Nektar Therapeutics NASDAQ: NKTR is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body's immune system to treat cancer and other serious diseases.

Nektar's product portfolio and pipeline include a range of clinical-stage and partnered programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.